{"id":"lixisenatide-glargine","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Nausea"},{"rate":"10–20","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Vomiting"},{"rate":"5–10","effect":"Diarrhea"},{"rate":"5–10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108336","moleculeType":"Protein"},"_dailymed":{"setId":"4bba538b-cf7c-4310-ae8f-cb711ed21bcc","title":"SOLIQUA 100/33 (INSULIN GLARGINE AND LIXISENATIDE) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lixisenatide is a GLP-1 receptor agonist that enhances postprandial insulin secretion in response to glucose, slows gastric emptying, and reduces glucagon secretion. Insulin glargine is a long-acting basal insulin that provides steady background insulin levels. The combination addresses both fasting and postprandial hyperglycemia in type 2 diabetes patients.","oneSentence":"Lixisenatide stimulates insulin secretion via GLP-1 receptor agonism, while glargine provides basal insulin coverage, together improving glycemic control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:42.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT06716424","phase":"PHASE4","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-06","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT07307235","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-15","conditions":"Type 2 Diabetes","enrollment":1316},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT07117240","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Warsaw","startDate":"2025-07-10","conditions":"Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes","enrollment":100},{"nctId":"NCT05114590","phase":"PHASE4","title":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-01-27","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT03798080","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-19","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT03767543","phase":"PHASE3","title":"Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":265},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT03130426","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-06-27","conditions":"Type 2 Diabetes Mellitus","enrollment":161},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03881995","phase":"PHASE4","title":"Effects of Insulin Glargine and Lixisenatide on the Brain","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2019-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT02752412","phase":"PHASE3","title":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":513},{"nctId":"NCT02749890","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":321},{"nctId":"NCT02713477","phase":"PHASE1","title":"Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-04","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02752828","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-23","conditions":"Type 2 Diabetes Mellitus","enrollment":521},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT02168491","phase":"PHASE3","title":"Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2014-11","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT02058147","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-02","conditions":"Type 2 Diabetes","enrollment":1170},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT02767596","phase":"PHASE4","title":"Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog","status":"TERMINATED","sponsor":"Laniado Hospital","startDate":"2016-07-12","conditions":"Diabetes Mellitus Type 2","enrollment":2},{"nctId":"NCT01476475","phase":"PHASE2","title":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":323},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT01596504","phase":"PHASE2","title":"Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":142},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT02200991","phase":"PHASE4","title":"Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":136},{"nctId":"NCT02276196","phase":"PHASE4","title":"Effect of LIXIsenatide on the Renal System","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-09","conditions":"Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus","enrollment":40},{"nctId":"NCT01910194","phase":"PHASE2","title":"Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2013-12","conditions":"Diabetes Mellitus","enrollment":39},{"nctId":"NCT01146678","phase":"PHASE1","title":"Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06","conditions":"Type 1 Diabetes Mellitus","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GLP-1 plus basal insulin"],"phase":"marketed","status":"active","brandName":"lixisenatide + glargine","genericName":"lixisenatide + glargine","companyName":"Medical University of Warsaw","companyId":"medical-university-of-warsaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lixisenatide stimulates insulin secretion via GLP-1 receptor agonism, while glargine provides basal insulin coverage, together improving glycemic control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}